Micromet, Inc. (MITI) rated Outperform with price target $8 by MP Advisors
MP Advisors rated Outperform Micromet, Inc. (NASDAQ: MITI) on 04/06/2011, when the stock price was $5.90. Since
then, Micromet, Inc. has gained 86.27% as of 03/07/2012's recent price of $10.99. If you would have followed this MP Advisors's recommendation on MITI, you would have gained 86.27% of your investment in 336 days.
(Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company?s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin?s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.
helped investors navigate the dynamic BioPharma industry for decades. Our flagship BioPharmaceutical Outlook™ maps the highs and lows of the year, assessing the critical success factors that can shape the industry's future.